2020 American Transplant Congress
Lack of Drug-Drug Interaction between Maribavir and Voriconazole
*Purpose: Maribavir is being evaluated in Phase 3 trials for the treatment of cytomegalovirus infections in transplant recipients. These patients often take numerous concomitant medications,…2020 American Transplant Congress
Evaluation of Optimization of Workflow for Timing of Inpatient Therapeutic Drug Monitoring of Maintenance Immunosuppressive Drugs in Abdominal Transplant Recipients
Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL
*Purpose: Therapeutic drug monitoring (TDM) is essential to the safety and efficacy of immunosuppressants (IS) given their narrow therapeutic index. After an internal review, it…2020 American Transplant Congress
Relationship between Tacrolimus Intrapatient Variability and Medication Adherence in Kidney Transplant Recipients
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Intrapatient variability (IPV) has been established as a risk factor for poor post-transplant outcomes. IPV is frequently proposed to be related to nonadherence but…2020 American Transplant Congress
Basiliximab Induction in the Obese: One Size Does Fit All
*Purpose: Surgical advancements allow more obese (BMI> 30 kg/m2) patients to receive a renal transplant. The original clinical and pharmacokinetic (PK) trials in transplantation immunosuppression…2020 American Transplant Congress
Enough Initial Tacrolimus Blood Concentration is Crucial Even with Additional Everolimus in Corticosteroid Early Withdrawal Regimen for Kidney Transplant Recipients
*Purpose: Everolimus (EVR) in combination with low-dose calcineurin inhibitor has been demonstrated in clinical trials to have comparable efficacy in low immunological risk kidney transplant…2020 American Transplant Congress
Pharmacokinetics of Maribavir in Subjects with Moderate Hepatic Impairment
*Purpose: Maribavir, an investigational agent for cytomegalovirus (CMV) infection in transplant recipients, has received Breakthrough Therapy Designation. Maribavir is metabolized primarily in the liver through…2020 American Transplant Congress
De Novo Dosing of LCP-Tacrolimus Using Conservative Weight-Based Strategy Resulted in Supratherapeutic Trough Levels in Majority of Patients
University of Virginia Health System, Charlottesville, VA
*Purpose: Due to ongoing national drug shortages, our center transitioned to de novo use of LCP-tacrolimus (LCPT) in kidney transplant patients using a conservative dosing…2020 American Transplant Congress
Natural History of Tacrolimus Intrapatient Variability During the First Post-Transplant Year
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: High tacrolimus intrapatient variability (IPV) is associated with inferior outcomes in solid organ transplantation. Many evaluations of IPV empirically exclude the early post-transplant period…2020 American Transplant Congress
The Effects of Rivaroxaban and Apixaban on Tacrolimus Pharmacokinetics
*Purpose: To clarify the pharmacokinetic impact of rivaroxaban (RIVA) and apixaban (APIX) on tacrolimus (TAC) concentrations.*Methods: Solid organ transplant recipients 18-years or older who were…2019 American Transplant Congress
The Reduced Tacrolimus Metabolism Rate and Its Association with Estimated Glomerular Filtration Rate and Interstitial Fibrosis: A Study Using Korean Organ Transplantation Registry (KOTRY) Dataset
*Purpose: Tacrolimus is the key drug in clinical transplant, which has narrow therapeutic index. A few studies reported the association of tacrolimus metabolism rate with…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 12
- Next Page »